Measuring silent MS progression with advanced tests
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study is looking for people with MS who are already on a monoclonal antibody therapy. It aims to measure subtle signs of disease progression using advanced tests, even if you feel stable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with relapsing-remitting or primary progressive MS (using the 2017 McDonald criteria).
- You are currently being treated with a monoclonal antibody like natalizumab, ofatumumab, or ocrelizumab.
- Your disability level is at or below 7.0 on the EDSS scale (you can walk with or without help).
- You have not had an MS relapse or received IV steroids in the past 6 weeks.
- You are not pregnant, and you are not taking any other immune-suppressing medications besides the monoclonal antibody.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well different treatments, including bone marrow transplant, alemtuzumab, ocrelizumab, and ofatumumab, work for people with relapsing-remitting MS who have active disease. It will help doctors understand which therapy might slow disease progression best.
This study looks at people with relapsing-remitting multiple sclerosis (RRMS) to find factors that predict disability progression even when they are not having relapses. It may help doctors understand who is at higher risk and guide treatment decisions.
This study looks at “subclinical markers,” meaning early or hidden body changes that may show how relapsing-remitting multiple sclerosis (MS) is doing even when symptoms seem mild. It may help researchers find better ways to monitor MS and detect changes sooner.
This study looks at how certain brain changes relate to disability in people with multiple sclerosis (MS). It aims to see if measuring brain volume loss can help predict disease progression, which might help tailor treatments.
This study looks at whether MS relapses happen without any signs of new disease activity on an MRI scan. By tracking your symptoms and scans, researchers hope to better understand how MS affects people in real life. If you qualify, you may help improve future treatment decisions.
This study follows people with multiple sclerosis (MS) to see how the disease progresses over time. By tracking your health, researchers hope to learn more about MS and improve care.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.